Insmed, Inc.
INSM
$0.00
-1.47%
Insmed Inc is a biopharmaceutical company focused on respiratory, immunology, and rare diseases. It is a commercial-stage biotech with a core portfolio of two marketed products and a pipeline of clinical-stage programs.
INSM
Insmed, Inc.
$0.00
Related headlines
Investment Opinion: Should I buy INSM Today?
Based on a synthesis of the explosive growth potential, severe financial losses, and extreme valuation, the objective assessment is a Hold. While the growth narrative and analyst sentiment are compelling, the current price appears to fully reflect this optimism, leaving little margin for error. The stock is suitable only for investors with a very high risk tolerance, a long-term horizon, and a conviction in the company's ability to successfully develop its pipeline and eventually achieve profitability. It is not recommended for risk-averse or income-seeking investors.
Sign up to view all
INSM 12-Month Price Forecast
The outlook is bifurcated between tremendous growth potential and precarious financials/valuation. The base case is neutral, expecting the stock to trade within a wide range as it grapples with executing its growth plan against a backdrop of high expectations. The probability is weighted toward the base and bear cases due to the high degree of execution risk priced in.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
15 analysts
Implied Upside
—
vs. current price
Analyst Count
15
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for Insmed appears active, with 15 analysts providing estimates. The consensus estimated EPS for the upcoming period is $10.99, with a range from $8.54 to $14.08, and estimated revenue averages $6.47 billion. Recent institutional ratings from firms like Morgan Stanley, Mizuho, and Wells Fargo are uniformly positive, with actions including 'Overweight', 'Outperform', and 'Buy'.
Bulls vs Bears: INSM Investment Factors
Insmed presents a classic high-risk, high-reward biotech profile. Bullish drivers center on explosive revenue growth, a promising pipeline, and strong analyst support. Bearish concerns highlight extreme valuation, persistent deep losses, and high cash burn, making the stock sensitive to clinical and commercial execution risks.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue grew 152.6% YoY, showing strong commercial traction.
- Unanimous Analyst Optimism: 15 analysts provide positive ratings (Overweight/Outperform/Buy), signaling strong institutional confidence.
- Robust Pipeline Potential: Multiple clinical-stage programs across respiratory, immunology, and rare diseases offer future catalysts.
- Strong Liquidity Position: Current ratio of 3.83 indicates ample short-term financial flexibility.
Bearish
- Extreme Valuation Multiples: PS ratio of 61.3 and EV/Sales of 57.0 imply very high growth expectations.
- Deep and Sustaining Losses: Net loss of $328.5M in Q4 2025; negative ROE (-172.8%) and ROA (-29.0%).
- High Cash Burn: Trailing twelve-month free cash flow is -$997.6 million, raising funding concerns.
- Elevated Stock Volatility: Recent 35.7% drawdown from highs and high beta (1.17) indicate significant price risk.
INSM Technical Analysis
The stock has exhibited significant volatility over the past six months, with a sharp rally from around $152 in October 2025 to a peak above $211 in December, followed by a substantial correction. The overall trend from the start of the provided data (Oct 2025) to the current price of $163.52 shows a modest gain of about 7.0%. In the short term, the stock is down 6.04% over the last three months but has rebounded 9.50% over the past month, significantly outperforming the broader market. The current price of $163.52 sits approximately 23% below its 52-week high of $212.75 and is well above its 52-week low of $60.4, indicating it is in the upper half of its annual range despite recent declines.
Beta
1.10
1.10x market volatility
Max Drawdown
-35.7%
Largest decline past year
52-Week Range
$60-$213
Price range past year
Annual Return
+121.2%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | +10.5% | -4.3% |
| 3m | -8.3% | -4.0% |
| 6m | +3.4% | -2.0% |
| 1y | +121.2% | +22.2% |
| ytd | -8.3% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Revenue for Q4 2025 was $263.8 million, showing strong year-over-year growth of 152.6%. However, the company remains deeply unprofitable, with a net loss of $328.5 million in the same quarter and a trailing twelve-month free cash flow of -$997.6 million. Financial health is a concern, with a debt-to-equity ratio of 1.04, though it maintains a strong current ratio of 3.83. Operational efficiency metrics are negative, with a return on equity of -172.8% and a return on assets of -29.0%, reflecting the heavy investment phase and significant losses.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the company's negative net income and EBITDA, the Price-to-Sales (PS) ratio is the most relevant valuation metric. The current PS ratio is 61.3, and the Enterprise Value-to-Sales (EV/Sales) is 57.0. These figures indicate a very high sales-based valuation, typical for a commercial-stage biotech with significant growth expectations but no current profits. Peer comparison data is not available in the provided inputs.
PE
-29.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk for Insmed is financial sustainability. The company is burning over $1 billion annually in free cash flow while carrying significant debt (debt-to-equity of 1.04). This necessitates future capital raises, which could be dilutive to shareholders, especially if market sentiment sours or clinical trials disappoint. The valuation risk is extreme; with a Price-to-Sales ratio above 60, the stock price embeds near-perfect execution and blockbuster pipeline success. Any setback in revenue growth for its marketed products (Arikayce, Brinsupri) or negative data from key clinical programs (e.g., brensocatib, INS1201) could trigger a severe de-rating. Furthermore, the stock's high beta and recent volatility demonstrate its sensitivity to broader market risk-off sentiment, which could pressure the stock irrespective of company-specific news.
FAQ
The key risks are financial and clinical. The company is burning over $1 billion annually in cash and remains deeply unprofitable (ROE of -172.8%), risking future dilutive financing. Its extreme valuation (PS 61.3) makes it vulnerable to any growth slowdown or pipeline setback. Furthermore, the stock's high beta (1.17) means it will likely fall sharply in a broader market downturn.
The 12-month outlook is highly uncertain with a wide potential range. The base case (50% probability) suggests a trading range of $150-$200, driven by meeting revenue estimates but facing valuation pressure. A bull case (25%) could see a retest of the 52-week high ($212.75) or higher on stellar execution. A bear case (25%) could see a decline toward $100-$140 on growth disappointments or clinical setbacks.
Based on traditional metrics, INSM appears significantly overvalued. With a negative P/E and a Price-to-Sales ratio of 61.3, the stock is priced for nearly flawless future execution and blockbuster pipeline success. This valuation is justified only if the company meets its high revenue targets (consensus ~$6.47B) and eventually achieves profitability, which is a highly uncertain outcome.
INSM is a high-risk, high-potential stock. It is a 'good buy' only for aggressive investors who believe in its long-term pipeline and can tolerate extreme volatility and potential losses. The current valuation (PS ratio of 61.3) is very high, leaving little room for error. Most investors should consider it a speculative hold rather than a core purchase at this price.
INSM is strictly a long-term investment (5+ years). The company's value hinges on the successful development and commercialization of its pipeline, which will take years. Short-term trading is extremely risky due to the stock's high volatility and sensitivity to clinical trial news and quarterly revenue figures. This is not a stock for short-term investors or those needing capital preservation.